Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033958 | 0.73 | HDAC6 (0.50) | BCAT2 | |
| SCHEMBL29941849 | 0.72 | MKNK1 (0.55) | MKNK1MKNK2BCAT2KEAP1NFE2L2 | |
| SCHEMBL8668460 | 0.71 | BCAT2 (0.74) | MKNK1MKNK2BCAT2KEAP1NFE2L2 | |
| SCHEMBL6273046 | 0.71 | MKNK1 (0.44) | MKNK1MKNK2BCAT2KEAP1NFE2L2 | |
| SCHEMBL3453931 | 0.70 | HNF4A (0.53) | MKNK1MKNK2BCAT2KEAP1NFE2L2 | |
| SCHEMBL28262741 | 0.69 | PARP1 (0.48) | BCAT2 | |
| SCHEMBL2943710 | 0.68 | MKNK1 (0.50) | MKNK1MKNK2BCAT2KEAP1NFE2L2 | |
| SCHEMBL28264223 | 0.67 | MKNK1 (0.61) | MKNK1MKNK2BCAT2CHEK2PARP10 | |
| SCHEMBL4067133 | 0.66 | CA12 (0.57) | MKNK1MKNK2BCAT2CHEK2PARP10 | |
| SCHEMBL21629968 | 0.66 | BCAT2 (0.46) | BCAT2KEAP1NFE2L2PDK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271289-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060241179-A1 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241179-A1 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | MKNK1 86/4885MKNK2 85/4885BCAT2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.